Various Ca-channel blockers differ in cardiovascular action despite common effects at the Ca channel. Many investigators have reported only a single high-affinity receptor for binding of [3H]nitrendipine, a dihydropyridine Ca-channel blocker. Its equilibrium dissociation constant (Kd) does not match the concentration of nitrendipine needed for a physiological effect on the mammalian cardiac Ca channel. The purpose of these studies was to clarify the existing discrepancy between pharmacological properties of nitrendipine receptors and the physiological effects of the dihydropyridine blockers. (8-11). These "low-affinity" physiological effects of nitrendipine occur at a concentration 300-1000 times higher than the "high-affinity" [3H]nitrendipine binding to its receptor at <0.3 nM.
tional state of the Ca channel in smooth muscle, since the Kd value is similar to the concentration at which nitrendipine inhibits contraction. However, in contrast to numerous other studies, we observed that the predominant component of [3H] nitrendipine binding (95-99%) had a low-affimity Kd value (235 nM). This putative low-affinity [3H]nitrendipine receptor may correspond to the physiologically functional state of the Ca channel in cardiac muscle.
Voltage-sensitive Ca channels are essential for excitationcontraction coupling, impulse propagation, and metabolism in skeletal, cardiac, and smooth muscle cells (1, 2) . These channels appear to play a key role in the pathophysiology of a number of cardiovascular diseases (3) . Several major Ca-channel blocking agents with differing structures share a common mode of action at the cell membrane, inhibiting Ca entry into excitable cells. Despite this common action, these agents show differences in their cardiovascular effects. Possible explanations for these differences are that there are either (i) multiple subtypes of the Ca channel that show selective recognition for different blockers; (ii) multiple conformational states of the Ca channel that are determined by voltage, drugs, and other modifiers; or (iii) multiple sites on the Ca channel where different drugs interact.
Tritium-labeled dihydropyridine derivatives have been used to study pharmacological binding to the Ca channel (see refs. 4-6 for review). The relationship between binding of these radiolabeled dihydropyridine derivatives to the Ca channel and physiological block of Ca channels has remained unclear in many studies. Numerous studies by other groups have found a binding site in mammalian cardiac muscle for [3H]nitrendipine with a binding affinity (<0.3 nM) 2-3 orders of magnitude higher than the reported physiologically effective concentration of this compound (see refs. 4-6 for review). Initial voltage-clamp measurements of the physiological effects of nitrendipine yielded an IC50 value of 154 nM in mammalian heart (7) . Studies of nitrendipine's negative inotropic effect on contraction of isolated mammalian cardiac tissue determined IC50 values of 150-250 nM (8) (9) (10) (11) . These "low-affinity" physiological effects of nitrendipine occur at a concentration 300-1000 times higher than the "high-affinity" [3H]nitrendipine binding to its receptor at <0.3 nM.
Recent electrophysiological studies (12) (13) (14) have shown voltage-dependent block of the Ca channel by dihydropyridine Ca-channel antagonists. Dihydropyridine blockers bind to the "inactivated" Ca channel with high-affinity and to the "resting" Ca channel with low-affinity. These electrophysiological data indicate that radiolabeled dihydropyridine blockers might also bind to the Ca channel with two affinities.
An essential criterion for the use of a radiolabeled ligand in the pharmacological characterization of a membrane receptor-that its binding properties correlate with its physiological effects-is clearly not satisfied in many previous studies (4) (5) (6) 
MATERIALS AND METHODS
The procedures used for measuring uptake of nitrendipinte are similar to those described in detail previously (16) trimmed of fat, great vessels, and atria and washed to remove blood. Ventricles were rapidly placed in solution I (154 mM NaCl/10 mM KCl/0.8 mM CaCl2/10 mM Mops, pH 7.4). Ventricular myocardium (3-5 g) was finely minced and homogenized in 35 ml of ice-cold solution I with a Brinkmann Polytron (PT-20 probe) at setting 5 for three 15-sec periods, between which the tissue was cooled on ice. The homogenate was centrifuged at 28,000 x g for 20 min; the microsomal pellet was resuspended in binding medium (50 mM Tris.HCl/1 mM CaCl2, pH 7.4) at a concentration of 3-6 mg (wet weight) of pellet per ml of medium.
Bovine aorta from freshly slaughtered calves were rapidly washed and suspended in solution I, finely minced, and homogenized as described above. A smooth muscle preparation was prepared as follows. Homogenate was centrifuged at 1000 x g for 15 min in 20%o (wt/vol) sucrose, the supernatant (Si) was removed, and the pellet was discarded. S, was centrifuged at 10,000 x g for 15 min, the supernatant (S2) was removed, and the pellet was discarded. S2 was centrifuged at 90,000 x g for 30 min, the supernatant was removed and discarded, and the pellet (P3) was resuspended in ice-cold binding medium at a concentration of2 mg (wet weight) ofP3 per ml by homogenizing with the Polytron for three 5- (16) . Binding experiments were conducted under a sodium vapor lamp to prevent breakdown of light-sensitive nitrendipine.
[3H]Nitrendipine was purchased from New England Nuclear and had a reported specific activity of 87 Ci/mmol (1 Ci = 37 GBq) and a radiochemical purity of >97%. Unlabeled nitrendipine was kindly supplied by Miles Laboratories.
[3H]Nitrendipine was dissolved in ethanol; nitrendipine was dissolved in 1% ethanol (17) (19) in the rat heart homogenate. The high-and low-affinity saturable components of [3H]nitrendipine uptake are characterized by maximum saturable capacities, MH and ML, and by equilibrium dissociation constants, KH and KL, respectively. An F test to determine the validity of adding a second, low-affinity binding component to fit the data in Fig.  1B indicates that the two-receptor model describes the data better than a one-receptor model at the P < 0.005 level. Although the parameters defining the high-affinity saturable component can be estimated well from these binding assays (MH = 14.6 -+-0.4 fmol/mg of wet weight; KH = 0.32 + 0.07 nM), the low-affinity binding sites are sparsely occupied and far from saturation, leading to large statistical uncertainties in the parameter estimates that preclude their quantitation from the binding curve in Fig. 1 alone. A statistical method (20) introduced by us to characterize properties of high-and low-affinity receptors for a radiolabeled ligand was used to characterize the low-affinity component of [3H] [3H]nitrendipine. Figs. 1 and 2 indicated that the two-receptor model described the data better than a one-receptor model at the P < 0.01 level.
The affinity of other Ca-channel antagonists at the two binding sites can be determined by studying their ability to competitively displace labeled nitrendipine. Fig. 3 shows a displacement curve at 1.5 nM [3H]nitrendipine, using unlabeled nifedipine as the competitor. Even at 15 ,M unlabeled nifedipine, a portion of the [3H]nitrendipine bound to the low-affinity [3H]nitrendipine receptor sites was not displaced, indicating that nifedipine is a far less potent Cachannel antagonist at the low-affinity site than is nitrendipine. In fact, both high-and low-affinity [3H]nitrendipine receptor sites bound nifedipine less tightly than nitrendipine [KH(nifedipine) = 1.0 ± 0.2 nM and KL(nifedipine) = 117 + 2.9 AM.]
The data in Fig. 3 provide a vivid demonstration of two populations of Ca-channel receptors with differing affinities for dihydropyridine Ca-channel blockers in rat cardiac membrane, showing two clearly separable displacement curves. This correlation fails to explain the presence of two types of [3H]nitrendipine receptors in both cardiac and smooth muscle membrane. Two hypotheses will be considered here: (i) [3H]nitrendipine binds to two conformational states of the Ca channel that are interconvertible and show different affinities for dihydropyridine blockers and (ii) two distinct populations of Ca channels are present, which show differing affinities for dihydropyridine blockers.
The first hypothesis to explain our ligand binding studies is provided by Bean (12) and Sanguinetti and Kass (13) , who have demonstrated voltage-dependent binding of dihydropyridine blockers to the Ca channel, with high-and lowaffinity binding occurring to Ca channels in the inactivated and resting conformations, respectively. Further, in patchclamp studies, Hess et al. (14) found that the channel shows three different modes of gating, depending upon voltage. Ca channels show high-affinity binding of dihydropyridine blockers in only one of these gating modes. Thus, all of these studies show that dihydropyridine affinity to the Ca channel is related to the voltage-dependent conformational state of the Ca channel.
These Recognizing that two different states of the [ Hinitrendipine receptor exist may be helpful in explaining the tissue specificity of different Ca-channel blockers and in developing more selective Ca-channel antagonists. Therapeutic effects of various Ca-channel blockers differ for treatment of arrhythmias, angina, and hypertension. These clinical effects suggest that Ca channels in cardiac and smooth muscle membranes may differ in their interaction with the available Ca channel blockers.
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